
样式: 排序: IF: - GO 导出 标记为已读
-
Characteristics and Survival Outcomes of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group on 175 Patients Am. J. Hematol. (IF 10.1) Pub Date : 2025-06-03
Eirini Katodritou, Efstathios Kastritis, Dimitra Dalampira, Nikolaos Kanellias, Vasiliki Labropoulou, Gerasimos Kyriakidis, Vasiliki Douka, Sosana Delimpasi, Dionysios Stoumbos, Emmanouil Spanoudakis, Sotirios Papageorgiou, Despina Fotiou, Annita-Ioanna Gkioka, Theodora Triantafyllou, Ioannis Ntanasis-Stathopoulos, Theodosia Papadopoulou, Kyriaki Tsirou, Aggeliki Sevastoudi, Aikaterini Daiou, FoteiniIn this multi-institutional retrospective study, we analyzed the characteristics and outcomes of 118 patients with solitary bone plasmacytoma (SBP) and 57 with extramedullary plasmacytoma (SEP) diagnosed over 30 years. We also evaluated the impact of systemic therapy (ST), which is not routinely recommended, compared to standard radiation therapy (RT). The median age was 62 years (range: 17–85). Treatment
-
Clinical Impact of Graft Cryopreservation on Allogeneic Stem Cell Transplantation: An Italian, Registry‐Based Study on Behalf of the “Gruppo Italiano Per Il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare” (GITMO) Am. J. Hematol. (IF 10.1) Pub Date : 2025-06-02
Irene Defrancesco, Virginia Valeria Ferretti, Patrizia Chiusolo, Domenico Russo, Chiara Nozzoli, Attilio Olivieri, Massimiliano Gambella, Irene Maria Cavattoni, Stefania Bramanti, Stella Santarone, Renato Fanin, Roberto Cairoli, Simona Piemontese, Matteo Parma, Francesco Onida, Alessandro Busca, Luca Castagna, Angela Cuoghi, Domenico Pastore, Nicola Mordini, Fabio Benedetti, Cristina Skert, Carlo BorgheroThe coronavirus disease 2019 (COVID‐19) pandemic created major challenges for allogeneic hematopoietic stem cell transplantation (allo‐HSCT). Scientific societies and authorities recommended cryopreserving grafts before starting conditioning regimens, despite limited data on the clinical impact. The Italian Group for Bone Marrow Transplantation (GITMO) conducted a registry‐based study involving 3492
-
Identification of a CAR‐Derived Clone by NGS‐Based MRD After Fully Human BCMA CAR T‐Cell Therapy in Multiple Myeloma Am. J. Hematol. (IF 10.1) Pub Date : 2025-05-30
Wenqiang Yan, Jiao Chang, Chenxing Du, Yuntong Liu, Rui Lv, Hesong Zou, Tengteng Yu, Shuaishuai Zhang, Tingyu Wang, Weiwei Sui, Shuhui Deng, Yan Xu, Wenyang Huang, Shuhua Yi, Dehui Zou, Jianxiang Wang, Lugui Qiu, Yujiao Jia, Gang AnB cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell therapy has significantly improved survival outcomes in patients with relapsed or refractory multiple myeloma (RRMM), achieving unprecedented depth of response compared to conventional salvage regimens [1-3]. Minimal residual disease (MRD) negativity has emerged as a strong predictor of favorable prognosis in this setting [4] and
-
Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Allografted in First Remission: From EBMT ALWP Am. J. Hematol. (IF 10.1) Pub Date : 2025-05-30
Ali Bazarbachi, Jacques‐Emmanuel Galimard, Iman Abou Dalle, Gérard Socié, Jurjen Versluis, Depei Wu, Matthias Eder, Hélène Labussière‐Wallet, Ibrahim Yakoub‐Agha, Johan Maertens, Edouard Forcade, Tobias Gedde‐Dahl, Goda Choi, Cristina Castilla‐Llorente, Frederic Baron, Eolia Brissot, Jordi Esteve, Arnon Nagler, Mohamad Mohty, Fabio CiceriAccording to the European LeukemiaNet (ELN) 2022 classification, acute myeloid leukemia (AML) patients with intermediate or adverse risk are offered allogeneic hematopoietic stem cell transplantation (allo‐HSCT) in first remission. In this EBMT study, we included 1735 adult AML patients with ELN‐2022 adverse‐risk cytogenetics allografted between 2010 and 2022 in first remission (67% de novo AML, median
-
Clinical Benefit of Early Daratumumab Use in Multiple Myeloma is Undefined Am. J. Hematol. (IF 10.1) Pub Date : 2025-05-29
Ruben Van Dijck, Zoran Erjavec, John‐John B. SchnogConflicts of Interest The authors declare no conflicts of interest.
-
CPX‐351 (Vyxeos) in Acute Myeloid Leukemia: Time to Move on? Am. J. Hematol. (IF 10.1) Pub Date : 2025-05-29
Naseema Gangat, Ayalew Tefferi -
Mean Corpuscular Hemoglobin Modulates HbF/F‐Cell and Clinical Response to Gene Therapy and Hydroxyurea in Sickle Cell Disease Am. J. Hematol. (IF 10.1) Pub Date : 2025-05-28
Martin H Steinberg, Abdullah Kutlar, Paola SebastianiWe hypothesized that mean corpuscular hemoglobin (MCH) modulates the distribution of fetal hemoglobin (HbF) among F-cells in sickle cell disease, and mathematically modeled a hypothetical HbF distribution among F-cells following gene therapy or during highly successful hydroxyurea (HU) treatment. HbF, the prime genetic modulator of the phenotype of sickle cell disease, is largely excluded from the
-
ALK+ Large B‐Cell Lymphoma With Novel ZNF296::ALK: A Morphologic Mimic of ALK+ Anaplastic Large Cell Lymphoma Am. J. Hematol. (IF 10.1) Pub Date : 2025-05-27
Wei J. Wang, Pei Lin, John M. Stewart, Guilin Tang, Shaoying Li, Sanam Loghavi, L. Jeffrey Medeiros, Jie XuConflicts of Interest The authors declare no conflicts of interest.
-
Impact of Conditioning Intensity on Clinical Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Relapse After First Transplantation Am. J. Hematol. (IF 10.1) Pub Date : 2025-05-23
Kazuki Yoshimura, Hideki Nakasone, Masaharu Tamaki, Hiroki Hosoi, Kazuaki Kameda, Naoyuki Uchida, Noriko Doki, Takahiro Fukuda, Satoshi Yoshihara, Yasuo Mori, Hirohisa Nakamae, Masatsugu Tanaka, Yuta Katayama, Tetsuya Eto, Yuta Hasegawa, Shuichi Ota, Satoshi Takahashi, Makoto Yoshimitsu, Fumihiko Ishimaru, Junya Kanda, Yoshiko Atsuta, Kimikazu YakushijinAlthough second allogeneic hematopoietic cell transplantation HCT (HCT2) is a potentially curative treatment for patients relapsing after their first HCT (HCT1), it is associated with higher non‐relapse mortality (NRM) compared with HCT1. Furthermore, while reduced‐intensity conditioning (RIC) in HCT2 might decrease NRM, there is no consensus on which patients may benefit from RIC. We retrospectively
-
A Phase 2 Trial of CPX‐351 Combined With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia Am. J. Hematol. (IF 10.1) Pub Date : 2025-05-22
Tapan M. Kadia, Wei‐Ying Jen, Alex Bataller, Alexandre Bazinet, Gautam Borthakur, Elias Jabbour, Wei Qiao, Nicholas J. Short, Koichi Takahashi, Ghayas C. Issa, Courtney D. DiNardo, Guillermo Montalban‐Bravo, Naveen Pemmaraju, Andrew Tran, Vanthana Bharathi, Sanam Loghavi, Amin M. Alousi, Uday Popat, Naval G. Daver, Farhad Ravandi, Hagop M. KantarjianOutcomes in patients with relapsed/refractory (RR) AML are poor. We sought to investigate if CPX‐531 in combination with venetoclax (CPX + VEN) was tolerable and effective in RR AML. This was a single institution phase 1b/2 trial of CPX + VEN. Patients aged ≥ 18 years with RR AML who were fit for intensive chemotherapy were eligible. Prior venetoclax exposure was allowed. The phase 1b portion followed
-
Correction to “Efficacy and Safety of Early‐Start Deferiprone in Infants and Young Children With Transfusion‐Dependent Beta Thalassemia: Evidence for Iron Shuttling to Transferrin in a Randomized, Double‐Blind, Placebo‐Controlled, Clinical Trial (START)” Am. J. Hematol. (IF 10.1) Pub Date : 2025-05-21
M. S. Elalfy, M. Hamdy, A. Adly, et al., “Efficacy and Safety of Early-Start Deferiprone in Infants and Young Children With Transfusion-Dependent Beta Thalassemia: Evidence for Iron Shuttling to Transferrin in a Randomized, Double-Blind, Placebo-Controlled, Clinical Trial (START),” American Journal of Hematology 98, no. 9 (2023): 1415–1424, https://doi.org/10.1002/ajh.27010. In the acknowledgements
-
Corrigendum to “Pyruvate Kinase Function Correlates With Red Blood Cell Properties and Clinical Manifestations in Sickle Cell Disease” Am. J. Hematol. (IF 10.1) Pub Date : 2025-05-21
Traets M. J. M., J. F. Bos, S. van der Veen, et al., 2025. “Pyruvate Kinase Function Correlates With Red Blood Cell Properties and Clinical Manifestations in Sickle Cell Disease.” American Journal of Hematology 100, no. 5: 785–796. https://doi.org/10.1002/ajh.27644. In the original article, we inadvertently used the terms ‘univariate’ and ‘multivariate’ (Method section and Table 2). We, however, performed
-
PET/CT in the Staging and Treatment Response Assessment of Patients With Extranodal Marginal Zone Lymphoma Am. J. Hematol. (IF 10.1) Pub Date : 2025-05-21
Juan Pablo Alderuccio, Russ A. Kuker, Eduardo Edelman Saul, Michele D. Stanchina, Mark K. Polar, Jennifer Chapman, Wei Zhao, Rafael Hennemann Sassi, Craig H. Moskowitz, Isildinha M. Reis, Izidore S. Lossos -
Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Zanubrutinib in Immune Thrombocytopenia Am. J. Hematol. (IF 10.1) Pub Date : 2025-05-20
Qiu‐Sha Huang, Hai‐Xia Fu, Chen‐Cong Wang, Xiao‐Lu Zhu, Yun He, Jin Wu, Qi Chen, Peng Zhao, Zhuo‐Yu An, Kai‐Yan Liu, Xiao‐Jun Huang, Xiao‐Hui ZhangImmune thrombocytopenia (ITP) is characterized by impaired platelet production and increased platelet destruction. Zanubrutinib is a highly selective next‐generation Bruton tyrosine kinase (BTK) inhibitor that may reduce autoantibody production and reduce macrophage Fcγ receptor‐mediated platelet destruction. In this single‐arm, phase II study, we aimed to assess the efficacy and safety of zanubrutinib
-
Watching the Barn Door Open—Timing CML Stem Cell Allografts Am. J. Hematol. (IF 10.1) Pub Date : 2025-05-20
Jeffrey H. LiptonThe timing of your decision is just in important as the decision you make. John C. Maxwell The management of CML has evolved over the last quarter century or so, transforming this once fatal disease into one that is curable or at least controllable [1]. With the routine use of tyrosine kinase inhibitor (TKI) therapy, life expectancy is near normal compared to age-matched controls [2] although quality
-
Mixed Autoimmune Hemolytic Anemia: A Systematic Review of Epidemiology, Clinical Characteristics, Therapies, and Outcomes Am. J. Hematol. (IF 10.1) Pub Date : 2025-05-20
Jeremy W. Jacobs, Sheharyar Raza, Landon M. Clark, Laura D. Stephens, Elizabeth S. Allen, Jennifer S. Woo, Rachel Lane Walden, Cristina A. Figueroa Villalba, Christopher A. Tormey, Caroline G. Stanek, Brian D. Adkins, Evan M. Bloch, Garrett S. Booth -
Cystatin C as Biomarker for the Evaluation of Renal Outcome in AL Amyloidosis Am. J. Hematol. (IF 10.1) Pub Date : 2025-05-19
Foteini Theodorakakou, Despina Fotiou, Filia Apostolakou, Ioannis Papassotiriou, Vasiliki Spiliopoulou, Ioannis Ntanasis‐Stathopoulos, Panagiotis Malandrakis, Magdalini Migkou, Nikolaos Kanellias, Evangelos Eleutherakis‐Papaiakovou, Erasmia Psimenou, Asimina Papanikolaou, Charikleia Gakiopoulou, Smaragdi Marinaki, Stavroula Giannouli, Maria Gavriatopoulou, Evangelos Terpos, Meletios‐Athanasios DimopoulosCystatin C (CysC) has emerged as a novel and potentially more reliable biomarker for the estimation of glomerular filtration in the general population in patients with various conditions. In AL amyloidosis, the current renal staging system and renal response criteria are based on proteinuria and creatinine‐based eGFR. We explored the prognostic role of CysC and of estimation of eGFR based on CysC‐based
-
Classical and Late‐Onset SOS/VOD After Allogeneic HSCT: A Japanese Transplant Registry Analysis Am. J. Hematol. (IF 10.1) Pub Date : 2025-05-19
Kyoko Masuda, Keisuke Kataoka, Masatoshi Sakurai, Yuho Najima, Naonori Harada, Shoko Ukita, Naoyuki Uchida, Noriko Doki, Takahiro Fukuda, Masatsugu Tanaka, Hiroyuki Ohigashi, Jun Ishikawa, Satoshi Yoshihara, Masashi Sawa, Shuichi Ota, Yoshinobu Kanda, Tetsuya Nishida, Makoto Onizuka, Yoshiko Atsuta, Hideki Nakasone, Kimikazu YakushijinSinusoidal obstruction syndrome/veno‐occlusive disease (SOS/VOD) is a lethal complication of allogeneic hematopoietic stem cell transplantation (allo‐HSCT). According to the 2016 European Society for Blood and Marrow Transplantation criteria, SOS/VOD is classified into classical SOS/VOD and late‐onset SOS/VOD, but their similarities and differences remain unclear. Here we retrospectively investigated
-
Routine Screening of Strongyloides Among Patients With Lymphoma and Efficacy of Targeted Prophylaxis Am. J. Hematol. (IF 10.1) Pub Date : 2025-05-19
Michele D. Stanchina, Camila Sacher, Yamila Melendez, Pamela Dudkiewicz, Jose F. Camargo, Izidore S. Lossos -
Clinical Factors Associated With Catheter‐Related VTE in Patients Undergoing Hematopoietic Cell Transplantation: A Multi‐Center Study Am. J. Hematol. (IF 10.1) Pub Date : 2025-05-16
Navel Gopal Subramanian, Danielle Guffey, Jonathan Avery, David Garcia, Ryan Basom, Stephanie J. Lee, Katherine Klein, Partow Kebriaei, Gabriela Rondon, Elizabeth Shpall, Shida Jin, Elliana Young, Cristhiam Mauricio Rojas Hernandez, Ang LiVenous thromboembolism (VTE) is a clinically significant complication that occurs in patients undergoing allogeneic hematopoietic cell transplantation (HCT). Due to the prolonged need for indwelling central venous catheters (CVCs), the incidence of catheter-related deep venous thrombosis (CR-DVT) appears higher at 3%–4% than that of pulmonary embolism (PE) or lower extremity deep vein thrombosis (LE-DVT)
-
Adult Acute Lymphoblastic Leukemia: 2025 Update on Diagnosis, Therapy, and Monitoring Am. J. Hematol. (IF 10.1) Pub Date : 2025-05-16
Hagop Kantarjian, Elias JabbourDisease OverviewAcute lymphoblastic leukemia (ALL) is a disease of lymphoid progenitor cells arising in the bone marrow and extramedullary sites. While it is the most common pediatric cancer, ALL is a rare disease overall, with approximately 6500 new cases diagnosed in the United States, in 2024. Current treatment relies on multiagent chemotherapy administered over 2–3 years, resulting in long‐term
-
The Mutational Landscape in Polycythemia Vera: Phenotype, Genotype, and Prognostic Correlates Am. J. Hematol. (IF 10.1) Pub Date : 2025-05-15
Masooma S. Rana, Moazah Iftikhar, Yamna Jadoon, Maymona Abdelmagid, David S. Viswanatha, Rong He, Kaaren K. Reichard, Animesh D. Pardanani, Naseema Gangat, Ayalew Tefferi -
Total Metabolic Tumor Volume Is a Strong Independent Prognostic Factor in Follicular Lymphomas: Results From a Sub‐Study of the FOLL12 Trial Am. J. Hematol. (IF 10.1) Pub Date : 2025-05-14
Rexhep Durmo, Stephane Chauvie, Carla Minoia, Fabrizio Bergesio, Federico Fallanca, Simona Peano, Luigi Marcheselli, Antonella Anastasia, Carola Boccomini, Paolo Corradini, Jacopo Olivieri, Luca Arcaini, Federica Cavallo, Adalberto Ibatici, Luca Nassi, Vittoria Tarantino, Antonello Pinto, Caterina Stelitano, Alessandro Pulsoni, Francesca Ricci, Salvatrice Mancuso, Emanuele Cencini, Nicola Di Renzo -
Baseline Hemoglobin Values and Clinical Outcomes in Acute Venous Thromboembolism: Insights From the RIETE Registry Am. J. Hematol. (IF 10.1) Pub Date : 2025-05-13
Carmine Siniscalchi, Pierpaolo Di Micco, Antonella Tufano, Maria Luisa Peris, Patricia López-Miguel, Alicia Alda-Lozano, Pilar Llamas, Diego Durán Barata, Yaser Jenab, Manuel MonrealVenous thromboembolism (VTE) is a major global health concern and a leading cause of morbidity and mortality. While anticoagulation effectively reduces the risk of recurrent VTE, it is associated with an inherent risk of bleeding. Identifying patient characteristics that influence these risks is critical for personalized management. Baseline hemoglobin (Hb) values have emerged as a potential prognostic
-
-
Issue Information Am. J. Hematol. (IF 10.1) Pub Date : 2025-05-12
Click on the article title to read more.
-
Impact of Switching From Race‐Based to Race‐Neutral Spirometry Reference Equations in Children With Sickle Cell Anemia Am. J. Hematol. (IF 10.1) Pub Date : 2025-05-12
Jose A. Mejias‐Figueroa, Mark Rodeghier, Michael R. DeBaunThe American Thoracic Society now recommends race-neutral spirometry reference equations, as proposed by the Global Lung Initiative, which estimates lung function based solely on age, height, and sex [1]. However, the impact of this shift from race-based to race-neutral reference equations on the established relationship in children with sickle cell anemia between increasing age and decreasing FEV1%
-
Optimal Depth of the Treatment Response Before Allogeneic Hematopoietic Transplantation for Chronic Myeloid Leukemia in Chronic Phase Am. J. Hematol. (IF 10.1) Pub Date : 2025-05-12
Yosuke Okada, Takeshi Kondo, Takuya Miyazaki, Yutaka Shimazu, Yosuke Minami, Fumihiko Ouchi, Shinichi Kako, Masatsugu Tanaka, Tetsuya Nishida, Shin‐Ichiro Fujiwara, Naoyuki Uchida, Hirohisa Nakamae, Yuta Hasegawa, Keisuke Kataoka, Shingo Yano, Mamiko Sakata‐Yanagimoto, Ayumu Ito, Jun Ishikawa, Yoshinobu Kanda, Koji Kawamura, Takahiro Fukuda, Yoshiko Atsuta, Takayoshi TachibanaThe outcomes of chronic myeloid leukemia (CML) have dramatically improved since the introduction of tyrosine kinase inhibitors (TKIs) [1, 2]. The development of TKIs has improved the life expectancy in CML patients, which is approaching that in the general population. However, resistance and intolerance to TKIs can still occur, and allogeneic hematopoietic cell transplantation (allo-HCT) is still a
-
Hypoferremic Response to Chronic Inflammation Is Controlled via the Hemojuvelin/Hepcidin/Ferroportin Axis and Does Not Involve Hepcidin‐Independent Regulation of FpnmRNA Am. J. Hematol. (IF 10.1) Pub Date : 2025-05-10
Siqi Liu, Sofiya Tsyplenkova, Carine Fillebeen, Kostas Pantopoulos -
The Impact of Allogeneic Hematopoietic Stem Cell Transplantation on Sickle Cell Retinopathy and Maculopathy: A Prospective, Observational Study Am. J. Hematol. (IF 10.1) Pub Date : 2025-05-09
Rajani P. Brandsen, Elisabeth Dovern, Bart J. Biemond, Roselie M. H. Diederen, Erfan NurSickle cell retinopathy (SCR) represents a significant ocular manifestation of sickle cell disease (SCD) that can dramatically impair visual acuity. SCR can be divided into non-proliferative SCR and proliferative SCR. Non-proliferative SCR involves abnormalities of the peripheral retina such as vascular occlusion without neovascularization, typical scarring (“black sunbursts”) and intraretinal hemorrhages
-
Allogeneic Hematopoietic Stem Cell Transplantation for Elderly Acute Lymphoblastic Leukemia Patients: A Registry Study From the Société Francophone de Greffe de Moelle et Thérapie Cellulaire (SFGM‐TC) Am. J. Hematol. (IF 10.1) Pub Date : 2025-05-06
Yves Chalandon, Raynier Devillier, Ariane Boumendil, Stephanie Nguyen, Claude‐Eric Bulabois, Patrice Ceballos, Eolia Brissot, Marie‐Thérèse Rubio, Hélène Labussière‐Wallet, Johan Maertens, Patrice Chevallier, Natacha Maillard, Xavier Poiré, Cristina Castilla‐Llorente, Yves Beguin, Jérôme Cornillon, Sébastien Maury, Tony Marchand, Etienne Daguindau, Jacques‐Olivier Bay, Pascal Turlure, Magalie JorisThere are very limited data regarding the outcomes of elderly patients with acute lymphoblastic leukemia (ALL) who undergo allogeneic hematopoietic stem cell transplantation (alloHSCT). A total of 316 ALL patients aged ≥ 60 years who underwent alloHSCT between 2010 to 2022 were identified in the SFGM‐TC registry. The primary objective was to evaluate progression‐free survival (PFS), non‐relapse mortality
-
Optimizing Outcomes in Relapsed and Refractory Multiple Myeloma: Personalized Approaches and Adverse Event Management Am. J. Hematol. (IF 10.1) Pub Date : 2025-05-05
Eirini Katodritou, Evangelos Terpos, Suzanne Lentzsch, Shaji Kumar1 Introduction Advances in frontline therapies for multiple myeloma (MM) have notably increased the time patients spend on initial treatments, but relapses are still a reality. Almost all patients with MM who undergo standard therapies experience relapse. Patients refractory to a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody—along with those with relapsed MM who receive
-
PIEZO1 Activation-Mediated Generation of Transgene-Free Long-Term Hematopoietic Stem Cells Am. J. Hematol. (IF 10.1) Pub Date : 2025-05-04
Giorgia Scapin, Jennifer L. Cillis, Marie C. Goulard, Taylor C. Patch, Cintia E. Gomez Limia, Yichen Ding, Wenqiang Du, Priyanka R. Dharampuriya, Elliott J. Hagedorn, Heidi Anderson, Gabriel A. Musso, Caitlyn R. Curley, Emily M. Teets, Calum A. MacRae, Lalit Sehgal, Tzung K. Hsiai, Bradley W. Blaser, Dhvanit I. ShahThe development of engraftable, long-term reconstituting hematopoietic stem cells (LT-HSC) from human pluripotent stem cells (hPSC) has been a long-sought goal. Since HSCs are formed by a subset of endothelial cells in the ventral part of the dorsal aorta, we analyzed heartbeat-mediated pulsatile displacement experienced by the walls of the dorsal aorta in zebrafish embryos. We found that pulsation-mediated
-
Thrombotic Thrombocytopenic Purpura (TTP) Survivors Exhibit Impaired Stress Perfusion on Cardiac MRI Am. J. Hematol. (IF 10.1) Pub Date : 2025-05-03
Senthil Sukumar, Leah Danish, Yuchi Han, Spero Cataland -
Thrombocytopenia and Anemia After Cardiac Surgery Am. J. Hematol. (IF 10.1) Pub Date : 2025-05-02
Myriam Beshai, Nour Alhomsi, Theodore E. Warkentin1 Case Presentation An 83-year-old Caucasian female with hypertension, dyslipidemia, and diabetes presented to the hospital with acute chest pain, nausea, and diaphoresis; she had a previous history of coronary angioplasty (9 years prior). Acute non-ST segment elevation myocardial infarction (NSTEMI) was diagnosed based upon non-specific T wave abnormalities and high-sensitivity troponin-I rise (peak
-
Profound Thrombocytopenia and Dyspnea 11 Days After Cardiac Surgery Am. J. Hematol. (IF 10.1) Pub Date : 2025-05-01
Sebastian Vuong, Menaka Pai, Sarah Patterson, Theodore E. Warkentin1 Case Presentation A 59-year-old Caucasian female with hypertension and dyslipidemia presented to the hospital with dyspnea. Her platelet count was 7 × 109/L (reference range [RR], 150–400). Eleven days earlier, she had undergone an elective valve-sparing Bentall procedure (replacement of hemi-aortic arch) and ascending aorta repair with cardiopulmonary bypass (CPB) for aortic root aneurysm. Her postoperative
-
Improved Transplant Outcomes With Alternative Donors in Myelofibrosis: A 20‐Year Japanese Registry Analysis of Donor Sources and the Impact of Ruxolitinib Am. J. Hematol. (IF 10.1) Pub Date : 2025-05-01
Kazuki Sakatoku, Hirohisa Nakamae, Makoto Murata, Yutaka Shimazu, Katsuto Takenaka, Fumihiko Kimura, Naoyuki Uchida, Tetsuya Nishida, Takahiro Fukuda, Noriko Doki, Jun Ishikawa, Emiko Sakaida, Keisuke Kataoka, Shuichi Shirane, Masatsugu Tanaka, Hikaru Kobayashi, Masashi Sawa, Toshio Wakayama, Noboru Asada, Yasufumi Uehara, Makoto Yoshimitsu, Junya Kanda, Marie Ohbiki, Yoshiko Atsuta, Takayoshi Tachibana -
Integration of Optical Genome Mapping in the Cytogenomic and Molecular Work‐Up of Hematological Malignancies: Expert Recommendations From the International Consortium for Optical Genome Mapping Am. J. Hematol. (IF 10.1) Pub Date : 2025-04-30
Rashmi Kanagal‐Shamanna, Anna Puiggros, Isabel Granada, Gordana Raca, Katrina Rack, Mar Mallo, Barbara Dewaele, Adam C. Smith, Yassmine Akkari, Brynn Levy, Robert P. Hasserjian, Adela Cisneros, Marta Salido, Guillermo Garcia‐Manero, Hui Yang, M. Anwar Iqbal, Ravindra Kolhe, Francesc Solé, Blanca Espinet -
A Phase II Trial of Geriatric Assessment‐Guided Selection of Treatment Intensity in Older Adults With AML Am. J. Hematol. (IF 10.1) Pub Date : 2025-04-29
Vijaya R. Bhatt, Christopher S. Wichman, Thuy T. Koll, Alfred L. Fisher, Tanya M. Wildes, Michael Haddadin, Ann M. Berger, James O. Armitage, Sarah A. Holstein, Lori J. Maness, Krishna Gundabolu -
The Synthetic Image Crisis in Science Am. J. Hematol. (IF 10.1) Pub Date : 2025-04-28
Enrico M. Bucci, Angelo PariniConflicts of Interest Enrico M. Bucci is the owner of Resis Srl, a company dedicated to analysis and consultancy in the field of research integrity. Angelo Parini declares no competing interests.
-
Acute Megakaryoblastic Leukemia Masquerading as a Germ Cell Tumor Am. J. Hematol. (IF 10.1) Pub Date : 2025-04-28
Lindsay M. Olson, Mark Gurney, Marissa Li, Yuan Yao, Tucker Johnson, Horatiu Olteanu, Naseema Gangat -
Rocky Mountain Spotted Fever, a Lymphoma Mimic on Peripheral Blood Smear Am. J. Hematol. (IF 10.1) Pub Date : 2025-04-28
Patricia Lupu, Linnea Banker, Richard D. HammerConflicts of Interest The authors declare no conflicts of interest.
-
Integrating Optical Genome Mapping With TP53 FISH: A Synergistic Approach for Cytogenomic Analysis in Chronic Lymphocytic Leukemia Am. J. Hematol. (IF 10.1) Pub Date : 2025-04-25
Joanna Kamaso, Rocío García‐Serra, Marina Munné, María Rodríguez‐Rivera, Carme Melero, Sílvia Ramos‐Campoy, Marta Salido, Marta Lorenzo, Eva Gimeno, Joan Gibert, Peter Vandenberghe, Katrina Rack, Anna Puiggros, Barbara Dewaele, Blanca EspinetFluorescence in situ hybridization (FISH) is the gold standard technique for cytogenetic assessment in chronic lymphocytic leukemia (CLL). In addition, chromosome banding analysis (CBA) is recommended as part of testing to detect complex karyotypes (CK, ≥ 3 abnormalities in the same cell clone), especially as those with a high-CK (≥ 5 abnormalities) have a known worst outcome [1, 2]. Optical genome
-
Elotuzumab in Combination With Dose Reduced IMiDs and Dexamethasone for AL Amyloidosis Patients With Relapsed/Refractory Plasma Cell Dyscrasia and Advanced Organ Involvement Am. J. Hematol. (IF 10.1) Pub Date : 2025-04-25
Tobias Dittrich, Timon Hansen, Christoph R. Kimmich, Kaya Veelken, Anna Jauch, Marc S. Raab, Carsten Müller-Tidow, Ute Hegenbart, Stefan O. SchönlandSystemic light chain (AL) amyloidosis is a rare, life-threatening disorder characterized by toxic light chain deposition and multiorgan dysfunction [1, 2]. Standard treatment targets the clonal plasma cells, and daratumumab-based regimens have demonstrated rapid hematologic responses with significant organ recovery [3]. However, with the increasing use of daratumumab in early treatment regimens, there
-
Arginine Therapy for Pain in Sickle Cell Disease: A Phase‐2 Randomized, Placebo‐Controlled Trial Am. J. Hematol. (IF 10.1) Pub Date : 2025-04-24
Claudia R. Morris, Dunia Hatabah, Rawan Korman, Scott Gillespie, Nitya Bakshi, Lou Ann Brown, Frank Harris, Deborah Leake, Chris A. Rees, Kirshma Khemani, Elliott P. Vichinsky, Alexus Locke, Bridget Wynn, Mark A. Griffiths, Hagar Wilkinson, Polly Kumari, Lisa Sudmeier, Sruti Shiva, Carlton D. DampierWe present a prospective randomized, placebo‐controlled trial of intravenous arginine in patients 3–21 years hospitalized with sickle cell disease vaso‐occlusive pain episodes (SCD‐VOE) at two tertiary‐care children's hospitals. Participants were randomized into 1 of 3 arms: Standard‐dose (SD; 100 mg/kg/dose) every 8 h, Loading‐dose (200 mg/kg followed by SD), or Placebo. The primary outcome was total
-
Cost‐Effectiveness of Ferritin Screening Thresholds for Iron Deficiency in Reproductive‐Age Women Am. J. Hematol. (IF 10.1) Pub Date : 2025-04-16
Daniel Wang, Manraj Sra, Samira Glaeser‐Khan, Daniel Y. Wang, Ranya Moshashaian‐Asl, Satoko Ito, Adam Cuker, George GoshuaIron deficiency (ID) is a top five leading cause of disability‐adjusted life‐years in women of reproductive age around the world. Despite its enormous health burden, no screening guidelines exist for the detection and treatment of ID in women of reproductive age. We sought to determine the cost‐effectiveness of screening versus no screening for ID in women of reproductive age in the United States.
-
Autologous Transplant or CAR‐T as Consolidation Options in MYC Rearranged Large B‐Cell Lymphoma Patients in Remission After Salvage Treatments Am. J. Hematol. (IF 10.1) Pub Date : 2025-04-15
Fateeha Furqan, Kwang W. Ahn, Manmeet Kaur, Jinalben Patel, Stephen Ansell, Farrukh T. Awan, John Baird, Evandro Bezerra, Umar Farooq, Henry Fung, Arushi Khurana, Lazaros Lekakis, Forat Lutfi, John McCarty, Akash Mukherjee, Rajneesh Nath, Jason Romancik, Stephen J. Schuster, Melody Smith, Allison Winter, Cameron Turtle, Craig Sauter, Mazyar Shadman, Alex Herrara, Mehdi HamadaniAlthough recent studies have demonstrated the efficacy of chimeric antigen receptor T‐cell (CAR‐T) therapy in relapsed large B‐cell lymphoma (LBCL) with MYC rearrangement (R‐MYC), the data comparing CAR‐T to autologous hematopoietic cell transplant (auto‐HCT) in such patients who achieve a complete or partial response (CR/PR) after salvage therapies are limited. We compared the clinical outcomes of
-
The Impact of Melphalan Conditioning and CD34+ Cell Dose and Schedule on Post‐Transplant Outcomes in AL Amyloidosis Am. J. Hematol. (IF 10.1) Pub Date : 2025-04-11
Eli Muchtar, Vaishali Sanchorawala, Hamza Hassan, Ute Hegenbart, Stefan Schönland, Hans C. Lee, Muzaffar Qazilbash, Andrew Kin, Jeffrey Zonder, Eapen Jacob, Francis Buadi, Angela Dispenzieri, David Dingli, Sally Arai, Michelle Chin, Rajshekhar Chakraborty, Suzanne Lentzsch, Hila Magen, Eden Shkury, Caitlin Sarubbi, Heather Landau, Morie GertzThe optimal conditioning schedule and CD34+ cell dose for autologous stem cell transplantation (ASCT) for AL amyloidosis is unknown. Patients (n = 1704) who underwent ASCT for AL amyloidosis between 2003 and 2020 in 9 centers were included. Data on melphalan conditioning dose, number of conditioning days, whether a rest day between conditioning and stem cell infusion was given or not, and infused CD34+
-
Impact of Evolving WHO and ICC Classifications on Prognosis and Outcomes in AML Patients Undergoing Allogeneic Stem Cell Transplantation Am. J. Hematol. (IF 10.1) Pub Date : 2025-04-08
Jacob Jendro, Jule Ussmann, Dominic Brauer, Donata Backhaus, Lara Bischof, Maximilian Merz, Vladan Vucinic, Georg-Nikolaus Franke, Marco Herling, Klaus H. Metzeler, Uwe Platzbecker, Sebastian Schwind, Madlen Jentzsch -
Clonal Hematopoiesis and Thrombosis Am. J. Hematol. (IF 10.1) Pub Date : 2025-04-07
Cornelia Englisch, Cihan AyClonal hematopoiesis (CH) has been the focus of many research efforts in the last years and has emerged as a risk modifier for cardiovascular disease morbidity and mortality. While substantial evidence has accumulated regarding its impact on arterial system diseases, the connection with venous thrombosis has only recently been explored. Both clinical and preclinical evidence suggest that the magnitude
-
Clonal Hematopoiesis in Gulf War Veterans Am. J. Hematol. (IF 10.1) Pub Date : 2025-04-07
Christin B. DeStefano, Matthew D. Wilkerson, Joaquin Villar, Sarah Darmon, Clifton L. Dalgard, Wendy B. BernsteinVeterans of the 1990–1991 Gulf War (GW) endured exposures from oil well fire smoke, pesticides, burn pits, depleted uranium, jet fuel, chemical warfare, and nerve agents [1]. The National Academies of Science, Engineering, and Medicine have reported sufficient data to associate GW deployment with chronic multisystem illness and post-traumatic stress disorder, but owing to latency there are insufficient
-
Better Outcome Following Younger Haploidentical Donor Versus Older Matched Unrelated Donor Transplant for Fit Patients With Acute Myeloid Leukemia Transplanted in First Remission: A Study From the Global Committee and the Acute Leukemia Working Party of the EBMT Am. J. Hematol. (IF 10.1) Pub Date : 2025-04-07
Yishan Ye, Allain Thibeault Ferhat Berland, Myriam Labopin, Jia Chen, Depei Wu, Didier Blaise, Carmen Di Grazia, Edouard Forcade, Xiao‐jun Huang, Ibrahim Yakoub‐Agha, Urpu Salmenniemi, Patrice Chevallier, Ali Bazarbachi, Arnon Nagler, Eolia Brissot, Lin Li, Yi Luo, Yanmin Zhao, Mohamad Mohty, He Huang, Fabio Ciceri, Norbert Claude GorinDonor selection has a major impact on the results of allo-HCT. Human leukocyte antigen (HLA)-matched sibling donors (MSD) are considered preferred donors, but they are available for only a minority of patients. 10/10 HLA fully-matched unrelated donors (MUDs) or haploidentical donors (HAPLOs) are both important alternatives in the absence of MSDs, with growing evidence indicating comparable transplant
-
Development of Polygenic Risk Score for Persistent Albuminuria in Children and Adults With Sickle Cell Anemia Am. J. Hematol. (IF 10.1) Pub Date : 2025-04-05
Rima S. Zahr, Guolian Kang, Xu Zhang, Sara R. Rashkin, Csaba P. Kovesdy, Clifford Takemoto, Mitch Weiss, Jeffrey Lebensburger, Kenneth I. Ataga, Santosh L. Saraf -
Diagnosis of Duffy Null-Associated Neutropenia During Chemotherapy Am. J. Hematol. (IF 10.1) Pub Date : 2025-04-05
Zeni Kharel, Nicole Jean Rubin, Rachel J. David, Peter KouidesDuffy-null-associated neutrophil count (DANC), formerly known as “benign ethnic neutropenia,” refers to a reduced absolute neutrophil count (ANC) observed in individuals homozygous for a variant in the promoter of the atypical chemokine receptor 1 (ACKR1) gene. This physiological condition, prevalent among individuals of African and Middle Eastern descent, is characterized by neutropenia without an
-
Generating Off-the-Shelf Hematopoietic Stem Cells by “Stretching” Induced Pluripotent Stem Cells Am. J. Hematol. (IF 10.1) Pub Date : 2025-04-05
Lei Han, John D. CrispinoConflicts of Interest J.D.C. is an advisor to Alethiomics and receives research funding from Syndax. The other author declares no conflicts of interest.
-
Not All Tryptase Elevations Are due to Acquired Clonal Mast Cell Disorders: When Tryptase Gene Copy Number Analysis Becomes Critical Am. J. Hematol. (IF 10.1) Pub Date : 2025-04-04
Victoria L. Heigh, Kaaren K. Reichard, Abhishek A. MangaonkarConflicts of Interest The authors declare no conflicts of interest.
-
Correction to “Benefit of Axicabtagene Ciloleucel Versus Chemoimmunotherapy in Older Patients and/or Patients With Poor ECOG Performance Status With Relapsed or Refractory Large B-Cell Lymphoma After 2 or More Lines of Prior Therapy” Am. J. Hematol. (IF 10.1) Pub Date : 2025-04-04
Lunning, MA, Wang, HL, Hu, ZH, et al., 2024. “ Benefit of Axicabtagene Ciloleucel Versus Chemoimmunotherapy in Older Patients and/or Patients With Poor ECOG Performance Status With Relapsed or Refractory Large B-Cell Lymphoma After 2 or More Lines of Prior Therapy.” American Journal of Hematology 99, no. 5: 880–889. https://doi.org/10.1002/ajh.27283. In the author byline, a typographical error was
-
Issue Information Am. J. Hematol. (IF 10.1) Pub Date : 2025-04-04
Click on the article title to read more.
-
Prognostic Validation of the International Consensus (ICC) Re-Classification of Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC) Into Genetic Subcategories Am. J. Hematol. (IF 10.1) Pub Date : 2025-04-02
Ayalew Tefferi, Daniel A. ArberConflicts of Interest The authors declare no conflicts of interest.
-
Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta‐Analysis Am. J. Hematol. (IF 10.1) Pub Date : 2025-03-29
Joshua Richter, Ajay Nooka, Paula Rodríguez‐Otero, Fredrik Schjesvold, Eirini Katodritou, Emily Combe, Marianne Scott, Leanne Cooper, Indeg Sly, Nick Ballew, Jacopo Bitetti, Natalie Boytsov, Molly Purser, Simon McNamaraIn the Phase 3 DREAMM‐7 study of patients with relapsed/refractory multiple myeloma (RRMM) who received ≥ 1 prior therapy, belantamab mafodotin plus bortezomib and dexamethasone (BVd) demonstrated a progression‐free survival (PFS) benefit versus daratumumab plus bortezomib and dexamethasone (DVd). This study aimed to indirectly compare the efficacy of BVd against alternative regimens in this patient